Company intelligence / Profile preview
Guangzhou Henovcom Bioscience Co., Ltd.
Guangzhou, Guangdong, Chinaen.henovcom.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Henovcom has multiple new molecular entities in clinical development targeting unmet needs such as antiviral, anti-fibrotic, inflammation, and CNS disorders. Its lead program HNC364—a long acting injectable prodrug of rasagiline for Parkinson’s—has completed Phase I trials in the US. The company also develops innovative mRNA capping technologies used globally for research and commercial applications. Several assets are advancing through IND-enabling studies or early clinical phases in both China and the US.[1][2][9]
- Therapeutic areas
- OncologyPulmonologyNeurologyInfectious Diseases
- Modalities
- Small moleculesmRNA therapeutics and vaccinesProdrugsModified nucleotides/capping agents for mRNA synthesis[1][2][7]
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Guangzhou Henovcom Bioscience Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Henovcom Bioscience Co., Ltd..